lipids Tag

11 Dec

Posted at 19:47h in Author Interviews, Heart Disease, Lipids, PLoS
MedicalResearch.com Interview with: Prof. Erik Ingelsson, MD, PhD, FAHA Professor of Molecular Epidemiology and Andrea Ganna PhD student Uppsala University Medical Research: What is the background for this study? What are the main findings? Response: Coronary heart disease (CHD) comprises a major cause of morbidity and mortality throughout the world. Measurement of metabolites, small molecules, in the blood could allow earlier diagnosis and inform about mechanisms leading to CHD. We examined the metabolic profiles (including thousands of metabolites) of blood samples from more than 3,600 individuals from Sweden that had been followed-up for up to 10 years, and found two lipid-related metabolites, lysophosphatidylcholine and sphingomyelin that reduced the risk of developing coronary heart disease and another lipid metabolite, monoglycerides, that was instead associated with increased risk.

15 Oct

Posted at 01:24h in Author Interviews, JAMA, Lipids, UCSF
MedicalResearch.comInterview with: Mary Malloy, M.D. Co-director of the Adult Lipid Clinic and the director of the Pediatric Lipid Clinic UCSF Medical Center Medical Research: What are the main findings of the study? Dr. Malloy: We studied an individual whom we found to be homozygous for a rare loss of function mutation in apolipoprotein E. Because apolipoprotein E is necessary for clearance of lipoproteins from plasma, he has very high levels of cholesterol and triglycerides in blood, and unusual and very severe xanthomas. He had no evidence of neurocognitive or retinal defects.

02 Oct

Posted at 23:53h in Author Interviews, Lancet, Lipids
MedicalResearch.com Interview with: Dr. Raul Santos Unidade Clínica de Lipides InCor-HCFMUSP Sao Paulo, Brazil. Medical Research: What are the main findings of the study? Dr. Santos: Evolocumab 420 mg injected subcutaneously every 4 weeks reduced LDL-C by 31% on average, in relation to placebo, in Homozygous familial hypercholesterolemia patients that were using maximally tolerated lipid lowering therapy but not on lipid apheresis regimen. Patients were separated according to the type of LDL receptor mutation, those with at least one allele codifyng a defective mutation on the LDL receptor (residual receptor activity 2-25%) had on average a 41% reduction on LDL-cholesterol. The 2 patients  homozygotes with alleles that codify a null mutation )receptor activity < 2%), did not respond to treatment. This was expected since PCSK9 inhibitors need a functional LDL receptor do work. Basically they increase the expression of the receptor that facilitates the clearance from plasma of circulating LDL particles. In those patients with defective LDL receptor  mutations there was 24% reduction of lipoprotein(a) concentrations, an extra risk factor for cardiovascular disease in familial hypercholesterolemia patients.

22 Sep

Posted at 17:56h in Author Interviews, Diabetes, Lipids, Statins
\MedicalResearch.com Interview with: Prof. Moses Elisaf Professor of Internal Medicine University of Ioannina, Greece Medical Research: What are the main findings of the study? Dr. Elisaf: We evaluated the effects of rosuvastatin in two groups of hyperlipidemic patients: one group had impaired fasting glucose (IFG) while the second group had normal fasting glucose. After study end, both groups had similar changes in their lipidemic profile. However, patients with IFG had a significant greater decrease in the cholesterol concentration of the more atherogenic small dense low-density lipoprotein (sdLDL) particles (-65.7%) compared with controls (-38.5%). Moreover, a greater increase in the mean LDL particle size was observed in the impaired fasting glucose group (+1.5% vs +0.4%). In addition, redistribution from the more atherogenic sdLDL to large buoyant LDL (lbLDL) subfractions was observed in the IFG group.

14 Jul

Posted at 22:25h in AHA Journals, Author Interviews, Lipids
Sripal Bangalore, MD, MHA, FACC, FAHA, FSCAI Director of Research, Cardiac Catheterization Laboratory Director, Cardiovascular Outcomes Group Associate Professor of Medicine, New York University School of Medcine Principal Investigator ISCHEMIA-CKD trialMedicalResearch.com Interview with: Sripal Bangalore, MD, MHA, FACC, FAHA, FSCAI Director of Research, Cardiac Catheterization Laboratory Director, Cardiovascular Outcomes Group Associate Professor of Medicine, New York University School of Medcine Principal Investigator ISCHEMIA-CKD trial Medical Research: What are the main findings of the study? Dr. Bangalore: Our objective was to evaluate whether non-fasting LDL has similar prognostic significance as that of the conventionally measured fasting LDL values. We found that in an analysis of over 16,000 patients from the National Health and Nutrition Examination Survey that the non-fasting LDL values had similar prognostic significance as that of fasting LDL values for the prediction of long term (up to 14 years) death or cardiovascular death, thus questioning the traditional practice of insisting that patients fast prior to blood draw for a lipid panel. This was also true for other components of the lipid panel including the triglycerides and total cholesterol.

15 Mar

Posted at 12:36h in Author Interviews, NIH
Peter F. Schnatz, D.O. Associate Chair & Residency Program Director The Reading Hospital Department of OB/GYN Reading, PA 19612-6052MedicalResearch.com Interview with: Peter F. Schnatz, D.O. Associate Chair & Residency Program Director The Reading Hospital Department of OB/GYN Reading, PA  19612-6052 MedicalResearch.com: What are the main findings of the study? Dr. Schnatz: In a subsample of 576 women from the parent WHI CaD (calcium plus vitamin D supplementation)  trial* , there was a significant (38%) increase in mean serum 25OHD3 concentrations after two years (95% CI 1.29-1.47, p< 0.001) for women randomized to CaD (24.3ng/mL vs. 18.2 ng/mL). Women randomized to CaD had a 4.5 mg/dL mean decrease in LDL-C which was statistically significant.  After accounting for serum 25OHD3 concentration, the effect of CaD was attenuated, suggesting that higher concentrations of 25OHD3, in response to CaD supplementation, are associated with improved LDL-C. In observational analyses, higher concentrations of 25OHD3 were associated with significantly higher HDL-C along with significantly lower LDL-C and TG concentrations. * 1,000 mg of elemental calcium plus 400 IU of vitamin D3 daily

10 Nov

Posted at 23:04h in Author Interviews, Heart Disease, Pediatrics
MedicalResearch.com interview with: Martha Mullett, MD MPH Neonatology West Virginia Universty Ped&Neo 1 Medical Center Dr Morgantown, WV 26506Martha Mullett, MD MPH Neonatology West Virginia Universty Ped&Neo 1 Medical Center Dr Morgantown, WV 26506   MedicalResearch.com: What are the main findings of the study? Dr. Mullett: The unique findings in this study relate to differences in triglycerides (TG) in premature infants and small for gestational age (SGA) infants when in 5th grade, at which time the children are approximately 11 years old.  Premature infants have higher triglyceride levels in 5th grade than term infants.(p<.05)  This difference appears in those premature infants who become overweight/obese by this age, but this reaches only a trend level. (p=.058) SGA infants who become overweight/obese by 5th grade (BMI ≥ 85th percentile) have TG that are significantly higher than all other 5th grade groups.

23 Aug

Posted at 00:25h in Author Interviews, JAMA, Pediatrics
Bjarke Feenstra, Ph.D. Senior Research Scientist Statens Serum Institut Artillerivej 5, 2300 Copenhagen S DenmarkMedicalResearch.com Interview with: Bjarke Feenstra, Ph.D. Senior Research Scientist Statens Serum Institut Artillerivej 5, 2300 Copenhagen S Denmark MedicalResearch.com: What are the main findings of the study? Dr. Feenstra: We discovered a new genome-wide significant locus for infantile hypertrophic pyloric stenosis (IHPS) in a region on chromosome 11 harboring the apolipoprotein (APOA1/C3/A4/A5) gene cluster and also confirmed three previously reported loci. Characteristics of the new locus led us to propose the hypothesis that low levels of circulating lipids in infants are associated with increased risk of IHPS. We addressed this hypothesis by measuring plasma lipid levels in prospectively collected umbilical cord blood from a set of 46 IHPS cases and 189 matched controls. We found that levels were on average somewhat lower in the children who went on to develop the condition.

03 Jul

Posted at 12:43h in Author Interviews, Baylor College of Medicine Houston, Cost of Health Care, Heart Disease, JAMA
 MedicalResearch.com Interview with Salim S. Virani, MD, PhD Health Policy and Quality Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center of Excellence, and Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Texas MedicalResearch.com: What are the main findings of the study? Dr. Virani: The main findings of the study are that despite having cholesterol levels at goal (LDL cholesterol <100 mg/dL), about one-third of patients (9200 out of 27947) with coronary heart disease had repeat cholesterol testing in 11 months from their last lipid panel. As expected, no intervention was performed as a response to these lipid panels. Collectively, 12686 additional lipid panels were performed in these patients.  Among 13,114 patients who met the optional treatment target of LDL-C<70 mg/dL, repeat lipid testing was performed in 8,177 (62.3% of those with LDL-C<70) during 11 months of follow-up. Patients with a history of diabetes mellitus (odds ratio [OR], 1.16; 95% CI, 1.10-1.22), a history of hypertension (OR, 1.21; 95%CI, 1.13-1.30), higher illness burden (OR, 1.39; 95%CI, 1.23-1.57), and more frequent primary care visits (OR, 1.32; 95%CI, 1.25-1.39) were more likely to undergo repeat testing, whereas patients receiving care at a teaching facility (OR, 0.74; 95%CI, 0.69-0.80) or from a physician provider (OR, 0.93; 95%CI, 0.88-0.98) and those with a medication possession ratio of 0.8 or higher (OR, 0.75; 95%CI, 0.71-0.80) were less likely to undergo repeat testing.